Xalkori (crizotinib) — United Healthcare

Initial criteria

• Diagnosis of inflammatory myofibroblastic tumor (IMT) with ALK translocation

Reauthorization criteria

• Patient does not show evidence of progressive disease while on Xalkori therapy

Approval duration

12 months